Eli Lilly and Company (NYSE: LLY) Thursday reported a sharp increase in its fourth-quarter revenues. The pharmaceutical company's adjusted earnings more than
LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%
Categories
Health Care
MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided
PFE Earnings: Key quarterly highlights from Pfizer’s Q4 2024 financial results
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2024 earnings results today. Revenues increased 22% year-over-year to $17.8 billion. GAAP net income
Earnings Summary: Highlights of IDEXX’s Q4 2024 report
Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and net income for the fourth quarter of 2024.
AbbVie Q4 2024 adjusted earnings decline despite 6% revenue growth
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in
Earnings Summary: Highlights of HCA Healthcare’s Q4 2024 financial results
Hospital chain HCA Healthcare, Inc. (NYSE: HCA) on Friday announced financial and operating results for the fourth quarter of fiscal 2024. Fourth-quarter
Intuitive Surgical (ISRG) Earnings: 4Q24 Key Numbers
Intuitive Surgical Inc. (NASDAQ: ISRG) reported revenue of $2.41 billion for the fourth quarter of 2024, up 25% from the same period
Important takeaways from Abbott Laboratories’ Q4 2024 earnings report
Abbott Laboratories (NYSE: ABT) reported mixed results for the final months of fiscal 2024 and issued guidance for the first quarter and
Highlights of Abbott Laboratories (ABT) Q4 2024 results
Abbott Laboratories (NYSE: ABT) on Wednesday announced financial results for the fourth quarter of 2024, reporting an increase in sales and adjusted
JNJ Earnings: All you need to know about Johnson & Johnson’s Q4 2024 earnings results
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today. Reported sales increased 5.3% year-over-year to $22.5 billion. Operational
UnitedHealth Group (UNH) Q4 2024 Earnings: Key financials and quarterly highlights
UnitedHealth Group (NYSE: UNH) reported its fourth quarter 2024 earnings results today. Total revenues were $100.8 billion compared to $94.4 billion reported
Johnson & Johnson (JNJ) likely to report mixed results for Q4 2024
Johnson & Johnson (NYSE: JNJ) is set to publish its December-quarter report on January 22, amid expectations for mixed results. The company,
Earnings Summary: DexCom reports preliminary Q4 2024 results
DexCom, Inc. (NASDAQ: DXCM) has announced preliminary financial results for the fourth quarter of 2024, reporting an 8% increase in revenues. The
WBA Earnings: Walgreens Boots Alliance reports higher Q1 sales; results beat
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Friday reported an increase in net sales for the first quarter of 2025. Both sales
Earnings Preview: UnitedHealth looks poised to end FY24 on a positive note
UnitedHealth Group (NYSE: UNH), a leading provider of health insurance and healthcare services, is expected to report fourth-quarter earnings next week. The
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Walgreens Boots Alliance expected to report mixed Q1 2025 results
For Walgreens Boots Alliance, Inc. (NASDAQ: WBA), 2024 was a challenging year as it lost market share to competitors and closed several
“Gelteq has been continuously evolving to expand applications and audiences”
Gelteq Limited (NASDAQ: GELS) is a healthcare company specializing in the development and manufacturing of edible gel products, with a focus on
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company
Earnings Summary: A snapshot of CooperCompanies (COO) Q4 2024 results
Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the fourth quarter of 2024, reporting an increase in revenues and
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that